# Cartesian Therapeutics, Inc. (RNAC)

> Source: Nexqual · https://nexqual.com/RNAC · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Cartesian Therapeutics, Inc. (RNAC), nexqual.com/RNAC" · informational, not investment advice.

**Price:** USD 6.58 (+3.79% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 6.34 · day 6.39–6.78 · 52w 5.6–11 · market cap $199M · NGM

## Key facts
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 33.67 (range 16–44).
- Total return with dividends: 1Y -30.1% vs S&P 500 +18.1%; 5Y -94.9% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.01, revenue estimate $121K.

## Analysts
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 33.67 (low 16, high 44).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | HC Wainwright & Co. | Reiterated | Buy | $25 |
| 2026-09-29 | Needham | Reiterated | Buy | $40 |
| 2026-08-18 | Wedbush | Reiterated | Outperform | $38 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -30.1% | -94.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -30.2% | -44.7% |
| Volatility (annualized) | 81.3% | 93.2% |
| Max drawdown | -40.1% (Jul 2026→Oct 2026) | -95.4% (Oct 2021→Jun 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/RNAC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt